Revolution Other Operating Expenses from 2010 to 2024
| RVMDW Stock | 0.33 0.01 3.09% |
Other Operating Expenses | First Reported 2010-12-31 | Previous Quarter 498.8 M | Current Value 320 M | Quarterly Volatility 98.7 M |
Check Revolution Medicines, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Revolution Medicines,'s main balance sheet or income statement drivers, such as Net Interest Income of 49.5 M, Interest Income of 49.9 M or Interest Expense of 287.9 K, as well as many indicators such as Price To Sales Ratio of 294, Dividend Yield of 0.0 or PTB Ratio of 1.69. Revolution financial statements analysis is a perfect complement when working with Revolution Medicines, Valuation or Volatility modules.
Revolution | Other Operating Expenses |
Latest Revolution Medicines,'s Other Operating Expenses Growth Pattern
Below is the plot of the Other Operating Expenses of Revolution Medicines, Warrant over the last few years. Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Revolution Medicines,. It is also known as Revolution Medicines, overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. It is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. Revolution Medicines,'s Other Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Revolution Medicines,'s overall financial position and show how it may be relating to other accounts over time.
| Other Operating Expenses | 10 Years Trend |
|
Other Operating Expenses |
| Timeline |
Revolution Other Operating Expenses Regression Statistics
| Arithmetic Mean | 201,351,003 | |
| Geometric Mean | 186,520,127 | |
| Coefficient Of Variation | 49.00 | |
| Mean Deviation | 69,917,472 | |
| Median | 153,680,000 | |
| Standard Deviation | 98,669,704 | |
| Sample Variance | 9735.7T | |
| Range | 345.1M | |
| R-Value | 0.68 | |
| Mean Square Error | 5663.2T | |
| R-Squared | 0.46 | |
| Significance | 0.01 | |
| Slope | 14,961,637 | |
| Total Sum of Squares | 136299.9T |
Revolution Other Operating Expenses History
About Revolution Medicines, Financial Statements
Revolution Medicines, investors use historical fundamental indicators, such as Revolution Medicines,'s Other Operating Expenses, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Revolution Medicines,. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Other Operating Expenses | 498.8 M | 320 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Revolution Stock Analysis
When running Revolution Medicines,'s price analysis, check to measure Revolution Medicines,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revolution Medicines, is operating at the current time. Most of Revolution Medicines,'s value examination focuses on studying past and present price action to predict the probability of Revolution Medicines,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revolution Medicines,'s price. Additionally, you may evaluate how the addition of Revolution Medicines, to your portfolios can decrease your overall portfolio volatility.